Zylox-tonbridge Medical Technology Co., Ltd. Class H · HKEX:2190
Zylox-tonbridge Medical Technology Co., Ltd. Class H — H1 2026 Earnings Presentation
34 slides from Zylox-tonbridge Medical Technology Co., Ltd. Class H's earnings presentation, August 2026
Slide 1: 2026 Interim Results Presentation
Zylox-Tonbridge（2190.HK） 2026 Interim Results Presentation August 2026
Slide 2: Disclaimer
Disclaimer This presentation has been delivered to interested parties for information purposes only and upon the express understanding that such parties will use it only for the purposes set forth above, and it is not intended to form the basis of any investment decision or any decision to purchase
Slide 3: Contents
CONTENTS Financial Highlights Sales and Marketing R&D Prospects
Slide 4: 11 New NMPA Approvals in 2026H1
Leading Player in Neuro- and Peripheral Vascular Interventional Medical Device Market in China International Market Neurovascular Intervention Neuro-vascular Vascular Intervention Peripheral Industry Transformation vascular Innovation Aging Breakthrough Peripheral Vascular Intervention 11 New NMPA A
Slide 5: Business Highlights
Business Highlights Rapid Revenue & Profit Growth Business Progress (in RMB million) - 11 New NMPA Approvals in China in 2026H1 631.8 - Overall Gross Profit Margin: 73.4% 31.1% - Overseas Revenue +349.3% YoY (11.2% of total) 482.0 246.9 - Key Overseas: EMEA 76.2%, LatAm 15.9%, APAC 7.9% 40.0% 176.4
Slide 6: Financial Highlights
? zyLox t) TONBRIDGE O71 Financial Highlights
Slide 7: Refine Portfolios, Achieve High Growth and Steady Profit
Refine Portfolios, Achieve High Growth and Steady Profit Revenue sustained strong growth Net Profit / (Loss ) 2 from 2023 through 2026H1 1 (in RMB million) 2023A 2024A 2025A 2025H1 2026H1 Gross Profit 72.9% 71.6% 72.1% 71.2% 73.4% Margin： 1,057.5 2023-2025CAGR: 42% 379.4 782.5 31.1% 252.4 631.8 244.
Slide 8: Neurovascular - Steady Revenue Growth
Neurovascular - Steady Revenue Growth Revenue of Neurovascular Products Main Source of Revenue (in RMB million) % of Revenue :72.3% 67.5% 64.1% 63.3% 57.9% Flow Intracranial 676.3 Diverter Support Catheter 2023-2025CAGR: 33% 528.5 20.2% 381.8 366.0 Detachable Coil Clot Neurovascular 304.5 System (I
Slide 9: Peripheral-vascular - Rapid Revenue Growth
Peripheral-vascular - Rapid Revenue Growth Revenue of Peripheral-vascular Products Main Source of Revenue (in RMB million) 32.3% 35.9% 36.7% 39.1% Peripheral % of Revenue : 27.4% Drug PTA Fibered 379.4 Coated Balloon Detachable PTA Catheter Coil Occlusion Balloon System Catheter 2023-2025CAGR: Endov
Slide 10: Overseas Market Growth Accelerates, Overseas Revenue +349% YoY
Overseas Market Growth Accelerates, Overseas Revenue +349% YoY Overseas Revenue as % of 2025H1 vs 2026H1 Overseas Revenue Total Revenue Comparison 11.2% (in RMB million) 70.6 349.3% H1Total Revenue: RMB 631.8 million 15.7 Overseas Revenue Domestic Revenue Overseas Business Line 2025 H1 2026 H1 Break
Slide 11: Leverage scale advantages, continuously improve operational efficiency
Leverage scale advantages, continuously improve operational efficiency Selling and Distribution R&D Expenses Administrative Expenses Expenses % of Revenue % of Revenue % of Revenue 49% 31% 30% 22% 23% 25% 22% 18% 18% 18% 17% 12% 11% 12% 10% 2023 2024 2025 2025H1 2026H1 2023 2024 2025 2025H1 2026H1 2
Slide 12: Sufficient Cash and Efficient Operations to Support Rapid Growth
Sufficient Cash and Efficient Operations to Support Rapid Growth in the Coming Years Cash From Operating Activities 2026H1 Cash Status (in RMB million) (in RMB million) 2,600 2,389 194 129 2025H1 2026H1 2025A 2026H1 1.Total cash at end-2025 and 1H2026 include cash and cash equivalents, time deposits
Slide 13: Sales and Marketing
? zyLox () TONBRIDGE Sales and Marketing
Slide 14: VBPs: Process Nears Completion
VBPs: Process Nears Completion Key VBPs Completed Upcoming VBPs 2022 2023 2024 2025 2026H1 2026H2 Vascular Peripheral Intracranial Intracranial Microcatheter: Coils:Jilin Intracranial Flow Diverter : Closure Neuro Access Coils, Support PTA Balloon : Zhejiang 21-Province Support Hebei Alliance DCB: D
Slide 15: Global Deep Dive, Sustained Peripheral Business Growth
Global Deep Dive, Sustained Peripheral Business Growth Full-Scale Layout ·Breakthrough Innovation Accelerated expansion into overseas markets to unlock the second-growth curve Full-spectrum coverage of lower-limb arterial, venous and hemodialysis access to enrich the product portfolio Pipeline of in
Slide 16: Solidify Neurovascular Business for Long-term Growth
Solidify Neurovascular Business for Long-term Growth, Build Momentum for Global Expansion Brand Power ·Growth Leadership Retain leading position among domestic players Progressing hospital adoption with improving market share Positioned in the global neurology market Strengthen pipeline for intracra
Slide 17: Joint Management of Global Distribution Network & Dual-Brand Expansion
Joint Management of Global Distribution Network & Synergistic Dual-Brand Expansion Overseas Revenue Growth Revenue Share by Key Region Overseas Sales Revenue 70.6 2023-2025 CAGR: 349.3% 48.6 EMEA 76.2% 85% 22.6 Latin America 15.9% 14.3 15.7 APAC 7.9% 2023 2024 2025 2025H1 2026H1 (in RMB million) EME
Slide 18: Breakthroughs in European Direct Sales, Dual-Brand Synergy Deepens
Breakthroughs in European Direct Sales, Dual-Brand Synergy Deepens European Direct Sales Market Experienced Direct Sales Team • ~15-person direct sales team in Germany, Austria and France German • Core members bring 15–30 years of medical device experience, formerly at Abbott, y Medtronic, Penumbra,
Slide 19: Global Integration Accelerate Overseas Market Expansion
Global Integration Accelerate Overseas Market Expansion Key Milestones in the Acquisition Global Integration and Synergy Synergy in Unity 2026.01 Team Integration Cultural Integration Signing of acquisition An executive-led integration team With "Quality and Diligence" as a agreement merged sales an
Slide 20: R&D
? zyLox () TONBRIDGE 03 R&D
Slide 21: Key Product Pipeline: 2026-2028
Key Product Pipeline: 2026-2028 Peripheral-Vascular Interventional and Neurovascular Interventional Portfolio Vascular Closure Devices Portfolio Intracranial Intracranial Hemodia Peripheral Vascular Intracranial Intracranial Carotid Artery Embolization Ischemic Hemorrhagic Arterial Venous lysis Inte
Slide 22: One-stop Haemodialysis Access Maintenance Solution
One-stop Haemodialysis Access Maintenance Solution Scoring Balloon Scoring Catheter PTA Balloon Dilatation Catheter ZENFLOW Pufferfish TRANSFORMER Peripheral Scoring Catheter KINGKONG Peripheral High-Pressure Balloon Catheter The First Directional Scoring Balloon for Hemodialysis Access in China The
Slide 23: Orca: A Core Tool for Iliac Artery Stenosis & Occlusion
Orca: A Core Tool for Iliac Artery Stenosis & Occlusion Indications Balloon-Expandable Covered Stent ✓ Indicated for the treatment of stenotic and/or occlusive lesions in the common and external iliac arteries. Product Features ✓ Proprietary high-rigidity material: anti-calcification, anti-recoil &
Slide 24: Otter: World's First Thrombectomy Device
Otter: World's First Thrombectomy Device Thrombectomy Device Indications Indications ✓ For endovascular clearance of acute lower-limb DVT. Acute DVT >50% of all DVT; >70% with subacute cases, high unmet clinical demand. Product Features ✓ Combined thrombectomy/thrombolysis/aspiration enhances clot c
Slide 25: FALCO: China's 1st DFT Intracranial Aneurysm Embolization Assist Stent
FALCO : China's 1st DFT Intracranial Aneurysm Embolization Assist Stent DFT (Nitinol-Platinum Coated) ✓ Full radiopacity for accurate stent deployment & apposition, 4 markers for precise positioning “Lantern ✓ Flexible braided design for tortuous anatomy Technique” 20% Metal Coverage 12-month comple
Slide 26: Core Tool for Combating Cerebrovascular Malformations
Core Tool for Combating Cerebrovascular Malformations Indications Liquid Embolic System ✓ Core Non-Adhesive Embolic Product ✓ Use: Embolization for bAVM & DAVF ✓ bAVM: Vascular malformation→ ICH(intracranial hemorrhage) . 25-35% of young adult strokes (2nd leading cause of ICH, after hypertension).
Slide 27: Solving Challenges in Bifurcation Wide-Necked Aneurysms
Solving Challenges in Bifurcation Wide-Necked Aneurysms Recognized Treatment Challenge ✓ Ideal for Wide-Neck Bifurcation Aneurysms. Bifurcation Self-expandable Aneurysm Embolization Device aneurysms(40-60% of intracranial cases) ✓ Complex Shapes, Turbulent Flow, High Rupture Risk & Challenging Treat
Slide 28: Deepen with Integrity and Innovation, Progress Steadily for the Long Term
Deepen with Integrity and Innovation, Progress Steadily for the Long Term Products below received NMPA Innovative Medical Device Designation (2025-Jun 2026) Spino™ Orca™ Otter™ Self-expandable Carotid Artery Double- Peripheral Balloon Expandable Thrombectomy Aneurysm Embolization Layer Dense Mesh St
Slide 29: Prospects
O04 Prospects
Slide 30: Global Integration: Driven by Innovation & Lean
Global Integration: Driven by Innovation & Lean Deep Global Integration: Building an Integrated Resilient Global Platform Innovation-Driven: Building a VBPs International Lean Differentiated Product Portfolio Production Global High- Market Value Medical Device Consumables Full-category Layout amid L
Slide 31: Thank You
THANK YOU
Slide 32: Consolidated Balance Sheet
Consolidated Balance Sheet Year ended December 31 Six months ended June 30 RMB '000 2023 2024 2025 2026 Non-current assets Property, plant and equipment 538,540 628,253 666,122 684,284 Right-of-use assets 39,820 37,251 36,368 62,557 Intangible assets 9,686 28,010 40,743 229,935 Deferred tax assets -
Slide 33: Consolidated Balance Sheet
Consolidated Balance Sheet Year ended December 31 Six months ended June 30 RMB '000 2023 2024 2025 2026 Non-current liabilities Borrowings 15,534 Lease liabilities 1,859 1,502 1,349 22,091 Deferred tax liabilities 10,937 Redemption liabilities on equity shares 267,704 Deferred revenue 8,674 15,885 1
Slide 34: Consolidated Statements of Profit or Loss
Consolidated Statements of Profit or Loss Year ended December 31 Six months ended June 30 % of % of % of % of RMB '000 2023 2024 2025 2026 Revenue Revenue Revenue Revenue Revenue 527,754 100% 782,476 100% 1,057,488 100% 632036 100% Cost of sales -142,766 -27% -222,581 -28% -294,570 -28% -168,144 -27
Zylox-Tonbridge Medical Technology — H1 2026 Earnings Presentation on 6ix